Development of a new system for prediction of drug absorption that takes into account drug dissolution and pH change in the gastro-intestinal tract

被引:75
作者
Kobayashi, M [1 ]
Sada, N [1 ]
Sugawara, M [1 ]
Iseki, K [1 ]
Miyazaki, K [1 ]
机构
[1] Hokkaido Univ Hosp, Sch Med, Dept Pharm, Kita Ku, Sapporo, Hokkaido 0608648, Japan
关键词
intestinal absorption; prediction; Caco-2; human; screening;
D O I
10.1016/S0378-5173(01)00663-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A new system for prediction of drug absorption that takes into account drug dissolution and pH change in the gastro-intestinal tract was developed. In this new system, a drug (solid form) is added into a drug-dissolving vessel (pH 1.0) and the dissolved drug is transferred to a pH adjustment vessel (pH 6.0). Then the drug solution is transferred to the apical surface of Caco-2 cells, and the permeation rate of the: drug across a Caco-2 monolayer is determined. This system was able to predict the oral absorption ratios of ten water-soluble drugs in humans. Using this system, it was predicted that drugs that permeated Caco-2 at a rate of more than 0.1%, of the dose in 200 min would be almost completely absorbed after oral administration in humans. For a drug whose permeation ratio was less than 0.03%, the absorption ratio was predicted to be less than 30%,. This system also enabled prediction of the absorption rate and variability in the absorption of albendazole, a drug with poor water solubility. It also enabled assessment of the improvement in absorption using a solid dispersion of albendazole-polymers that improved the water solubility. The results suggest that this system is useful for oral absorption screening of new drugs and pharmaceutical products. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:87 / 94
页数:8
相关论文
共 15 条
[1]  
ESSED GGM, 1988, ARCH INT PHARMACOD T, V293, P295
[2]  
FUKUSHIMA M, 1990, CLIN REPORT, V24, P3215
[3]   Prediction of dissolution-absorption relationships from a dissolution/Caco-2 system [J].
Ginski, MJ ;
Polli, JE .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1999, 177 (01) :117-125
[4]  
GINSKI MJ, 1999, PHARM SCI 1
[5]   CLINICAL PHARMACOKINETICS OF ALBENDAZOLE IN PATIENTS WITH BRAIN CYSTICERCOSIS [J].
JUNG, H ;
HURTADO, M ;
SANCHEZ, M ;
MEDINA, MT ;
SOTELO, J .
JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 32 (01) :28-31
[6]   Improving the oral bioavailability of albendazole in rabbits by the solid dispersion technique [J].
Kohri, N ;
Yamayoshi, Y ;
Xin, H ;
Iseki, K ;
Sato, N ;
Todo, S ;
Miyazaki, K .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1999, 51 (02) :159-164
[7]  
Kohri N., 1998, Pharmacy and Pharmacology Communications, V4, P267
[8]  
MAEDA H, 1989, CHEMOTHERAPY, V37, P806
[9]   PHARMACOKINETICS OF ALBENDAZOLE IN MAN [J].
MARRINER, SE ;
MORRIS, DL ;
DICKSON, B ;
BOGAN, JA .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 30 (06) :705-708
[10]  
Nakashima M., 1992, Jpn. J. Clin. Pharmcol. Ther, V23, P515, DOI 10.3999/jscpt.23.515